Belimumab has been a ground-breaking therapy for patients with systemic lupus erythematosus. In this op-ed, Paul Sufka, M.D., reviews recent studies on belimumab which could lead to new uses.
Data from an international lupus cohort shows the factors that correlate with permanent damage to renal, pulmonary, and other body systems in lupus. Some of them are modifiable. In this video, the author discusses what can be averted.